Drug · CHEMBL685
MEBENDAZOLE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MEBENDAZOLE. Drugs and targets, record CHEMBL685. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL685
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Mebendazol, Mebendazole polymorph c, Mebendazolum, NSC-184849, Ovitelmin, Pantelmin, R 17,635, R-17635, Vermicidin, Zhihuanqing
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases21
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 21Source Open Targets
See all 21 diseasesTrials30
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03995680 | Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm | Phase 2 | 397 | 2020-07-20 | mebendazole | Its name | ClinicalTrials.gov |
| NCT02034162 | A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants | Phase 3 | 295 | 2016-11-04 | mebendazole | Its name | ClinicalTrials.gov |
| NCT01350271 | Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections | Phase 3 | 214 | 2013-04-22 | mebendazole polymorph a, mebendazole polymorph c | Its name | ClinicalTrials.gov |
| NCT03245398 | Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children | Phase 4 | 186 | 2019-06-17 | mebendazole | Its name | ClinicalTrials.gov |
| NCT00148629 | Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women | Phase 3 | 2,500 | mebendazole | Its name | ClinicalTrials.gov | |
| NCT01327469 | The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia | Phase 4 | 2,250 | mebendazole | Its name | ClinicalTrials.gov | |
| NCT01314937 | The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas | Phase 4 | 1,760 | mebendazole | Its name | ClinicalTrials.gov | |
| NCT00116493 | Severe Anemia Treatment Trials, Pakistan | Phase 3 | 1,009 | mebendazole | Its name | ClinicalTrials.gov | |
| NCT01050452 | Safety and Efficacy of Drug Combinations Against Trichuris Trichiura | 750 | mebendazole | Its name | ClinicalTrials.gov | ||
| NCT01050374 | Safety and Efficacy of Drug Combinations Against Schistosomiasis | 650 | mebendazole | Its name | ClinicalTrials.gov |
1 to 10 of 30
See all 30 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Chewable Tablet of Mebendazole vs Swallowable Tablet of Mebendazole: deaths from any cause | 0 of 197 | 0 of 196 | 393 | NCT03995680 | Trial comparisons |
| Chewable Tablet of Mebendazole vs Swallowable Tablet of Mebendazole: serious adverse events | 0 of 197 | 0 of 196 | 393 | NCT03995680 | Trial comparisons |
| Double-blind Mebendazole 500 mg vs Double-blind Placebo: Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period | 9 of 144 | 8 of 140 | 284 | NCT02034162 | Trial comparisons |
| Single 500 mg Dose of Mebendazole vs Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole: deaths from any cause | 0 of 93 | 0 of 93 | 186 | NCT03245398 | Trial comparisons |
| Single 500 mg Dose of Mebendazole vs Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole: serious adverse events | 0 of 93 | 0 of 93 | 186 | NCT03245398 | Trial comparisons |
Papers from its trials13
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 19535425 | RESULT | 1 | PubMed |
| 19176737 | RESULT | 1 | PubMed |
| 42486129 | DERIVED | 1 | PubMed |
| 41364144 | DERIVED | 1 | PubMed |
| 38563751 | DERIVED | 1 | PubMed |
| 35385794 | DERIVED | 1 | PubMed |
| 33150325 | DERIVED | 1 | PubMed |
| 31193620 | DERIVED | 1 | PubMed |
| 29673735 | DERIVED | 1 | PubMed |
| 26426270 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL685
GET https://conductscience.org/api/drugs/v1/CHEMBL685/diseases?page=2